Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists
about
Use of fibrates in the metabolic syndrome: A reviewA New Role for Browning as a Redox and Stress Adaptive Mechanism?Residual macrovascular risk in 2013: what have we learned?New Era of Lipid-Lowering DrugsNew peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.Lipid-lowering activity of Cow urine ark in guinea pigs fed with a high cholesterol diet.Identification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazoneEffects on Liver Lipid Metabolism of the Naturally Occurring Dietary Flavone Luteolin-7-glucoside.Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis.Critical review of non-statin treatments for dyslipoproteinemia.The ebbs and flows in the development of cholesterol-lowering drugs: prospects for the future.Early investigational drugs targeting PPAR-α for the treatment of metabolic disease.ApoA-I-Directed Therapies for the Management of Atherosclerosis.Selective peroxisome proliferator-activated receptor-α modulator K-877 efficiently activates the peroxisome proliferator-activated receptor-α pathway and improves lipid metabolism in mice.PPARs in the central nervous system: roles in neurodegeneration and neuroinflammation.Transcription factor binding site enrichment analysis predicts drivers of altered gene expression in nonalcoholic steatohepatitis.PPAR-α agonists are still on the rise: an update on clinical and experimental findings.Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia.In vivo interactions between α7 nicotinic acetylcholine receptor and nuclear peroxisome proliferator-activated receptor-α: Implication for nicotine dependence.Zinc status is associated with inflammation, oxidative stress, lipid, and glucose metabolism.Amelioration of diet-induced steatohepatitis in mice following combined therapy with ASO-Fsp27 and fenofibrate.Fibrates in the management of atherogenic dyslipidemia.Editor's Highlight: Clofibrate Decreases Bile Acids in Livers of Male Mice by Increasing Biliary Bile Acid Excretion in a PPARα-Dependent Manner.A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice.Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial.Structure-guided evolution of a 2-phenyl-4-carboxyquinoline chemotype into PPARα selective agonists: New leads for oculovascular conditions.Changes in peroxisome proliferator-activated receptor alpha target gene expression in peripheral blood mononuclear cells associated with non-alcoholic fatty liver disease
P2860
Q26765234-7FCD4D3B-A33C-42A6-A408-EA2ED8B99196Q26779252-F1BCC4FA-5945-42FF-8F0B-EE6CF04BE3BEQ26996039-30FFB507-FC50-44E6-9DCC-01E40A32032FQ28072298-12C68502-41AB-4434-9FEE-4F1FD9828C73Q34398065-BB1A0F43-47D5-4965-B0AE-DCB5F990763CQ34474496-B11F705D-BC12-4E66-B829-31763D7AEE9FQ34511474-D57FB260-6095-482E-97FC-F7F192A96597Q35737798-87A74851-6B23-4D59-9557-CCA2F375C239Q37640263-B1DF6CD2-C18F-4435-AD11-EA9E10A576EEQ38186099-7F65E374-82AE-46CF-9E7B-BA80C8C4E5E8Q38201960-4CC5C763-0102-4E36-998A-D9A29D1FE70EQ38325814-A2AD2EC7-26EA-454E-A318-170FBE0A8E1CQ38579703-8AF280A7-7454-4037-BE4E-08CF93C504C3Q39022770-D4CF86BE-8CD8-4FF2-942A-566B54D5FFCCQ39145017-4DE1218F-BAAE-41CB-90B4-C1909291FDD9Q39194277-7254F022-82E3-4A3B-BC96-4206C3C01DEEQ39200940-AFDB7F7D-0539-4B17-AFE4-23CD11E8430BQ42278957-83F46AE8-BCE2-41F3-B864-9CC5E7339BEFQ45054305-ACCC910A-4171-43F5-B5F2-A5E18655BF9AQ46297850-7AB86B69-C691-4AB4-A3C9-FFDDD4601265Q47104903-3F180A6B-7E65-4587-949B-0004EC425B8DQ49571281-D8BD2F63-2197-4AC6-87F2-D0C17A34CFBCQ49650135-CA40BB38-234D-4365-A5C8-A31AB62EFE49Q50320306-36437A36-34D0-4A48-A45D-C953BA9EE571Q52599940-D0E08CDF-9E82-4B6A-BB35-5CE447CBAC85Q52599996-24931163-01E9-448D-BC1E-B475FD64EE25Q59135837-0E720ACD-81E1-474E-BF91-5C00DBDC5034
P2860
Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Selective peroxisome prolifera ...... -activated receptor α-agonists
@en
type
label
Selective peroxisome prolifera ...... -activated receptor α-agonists
@en
prefLabel
Selective peroxisome prolifera ...... -activated receptor α-agonists
@en
P2860
P921
P356
P1476
Selective peroxisome prolifera ...... -activated receptor α-agonists
@en
P2860
P2888
P356
10.1186/1475-2840-12-82
P407
P5008
P577
2013-05-31T00:00:00Z
P5875
P6179
1030206204